Company Registration Number 07928073 (England and Wales)
THRIVE THERAPEUTIC SOFTWARE LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2026
PAGES FOR FILING WITH REGISTRAR
Celixir House
Stratford Business & Technology Park
Innovation Way, Banbury Road
Stratford-upon-Avon
Warwickshire
United Kingdom
CV37 7GZ
THRIVE THERAPEUTIC SOFTWARE LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Statement of changes in equity
3
Notes to the financial statements
4 - 9
THRIVE THERAPEUTIC SOFTWARE LIMITED
BALANCE SHEET
AS AT 31 MARCH 2026
31 March 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Intangible assets
3
2,444,773
2,873,895
Tangible assets
4
11,817
22,132
Investments
5
1
1
2,456,591
2,896,028
Current assets
Debtors
6
180,292
363,473
Cash at bank and in hand
83,047
39,419
263,339
402,892
Creditors: amounts falling due within one year
7
(1,011,334)
(973,218)
Net current liabilities
(747,995)
(570,326)
Total assets less current liabilities
1,708,596
2,325,702
Creditors: amounts falling due after more than one year
8
(8,298)
(19,120)
Accruals and deferred income
9
(1,029,785)
(1,086,863)
Net assets
670,513
1,219,719
Capital and reserves
Called up share capital
682,054
682,054
Share premium account
4,499,370
4,499,370
Profit and loss reserves
(4,510,911)
(3,961,705)
Total equity
670,513
1,219,719
THRIVE THERAPEUTIC SOFTWARE LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2026
31 March 2026
- 2 -

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 10 July 2026 and are signed on its behalf by:
Dr. J A Saez Fonseca
Director
Company registration number 07928073 (England and Wales)
THRIVE THERAPEUTIC SOFTWARE LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2026
- 3 -
Share capital
Share premium account
Profit and loss reserves
Total
£
£
£
£
Balance at 1 April 2024
682,054
4,499,370
(3,309,937)
1,871,487
Year ended 31 March 2025:
Loss and total comprehensive income
-
-
(651,768)
(651,768)
Balance at 31 March 2025
682,054
4,499,370
(3,961,705)
1,219,719
Year ended 31 March 2026:
Loss and total comprehensive income
-
-
(549,206)
(549,206)
Balance at 31 March 2026
682,054
4,499,370
(4,510,911)
670,513
THRIVE THERAPEUTIC SOFTWARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
- 4 -
1
Accounting policies
Company information

Thrive Therapeutic Software Limited is a private company limited by shares incorporated in England and Wales. The registered office is Celixir House, Stratford Business & Technology Park, Innovation Way, Banbury Road, Stratford-upon-Avon, Warwickshire, United Kingdom, CV37 7GZ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The directors have considered the outlook for the business including the effect of the current economic conditions. On the basis of sales and expenditure forecasts and in view of additional finance that in the opinion of the directors the company has a reasonable expectation of raising from external investors post year-end, the directors consider it appropriate to prepare the financial statements on the going concern basis.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable, net of discounts, sales tax and value added taxes. Turnover comprises revenue earned from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the transaction. The stage of completion of a transaction is generally measured for subscription-based revenue evenly over the period of subscription, and for other revenue by comparing the costs incurred for work performed to date to the estimated total costs.

1.3
Research and development expenditure

Research expenditure and non capital development costs are written off against profits in the year in which they are incurred. Development costs of a capital nature are capitalised as development costs and written off over a period of 5 years, or their useful economic life if shorter.

1.4
Intangible fixed assets other than goodwill

Intangible assets internally developed or acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

THRIVE THERAPEUTIC SOFTWARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 5 -

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs
written off over a period of 5 years, or their useful economic life if shorter
1.5
Tangible fixed assets

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computers
33.3% straight line
1.6
Share-based payments

The company provides share-based payment arrangements to certain employees. Equity-settled arrangements are measured at fair value (excluding the effect of non-market vesting conditions) at the date of grant. The fair value is expensed on a straight-line basis over the vesting period. The amount recognised as an expense is adjusted to reflect the actual number of shares or options that will vest.

Where equity-settled arrangements are modified, and are of benefit to the employee, the incremental fair value is recognised over the period from the date of modification to the date of vesting. Where a modification is not beneficial to the employee there is no change to the charge for share-based payment. Settlements and cancellations are treated as an acceleration of vesting and the unvested amount is recognised immediately in the profit and loss account.

The company has no cash-settled arrangements.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax. Tax is recognised in the Profit and Loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

THRIVE THERAPEUTIC SOFTWARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 6 -
Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

1.8

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

1.9

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
42
52
THRIVE THERAPEUTIC SOFTWARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 7 -
3
Intangible fixed assets
Development costs
£
Cost
At 1 April 2025
6,525,231
Additions - internally developed
687,447
At 31 March 2026
7,212,678
Amortisation and impairment
At 1 April 2025
3,651,336
Amortisation charged for the year
1,116,569
At 31 March 2026
4,767,905
Carrying amount
At 31 March 2026
2,444,773
At 31 March 2025
2,873,895
4
Tangible fixed assets
Computers
£
Cost
At 1 April 2025
172,890
Additions
4,247
Disposals
(583)
At 31 March 2026
176,554
Depreciation and impairment
At 1 April 2025
150,758
Depreciation charged in the year
14,562
Eliminated in respect of disposals
(583)
At 31 March 2026
164,737
Carrying amount
At 31 March 2026
11,817
At 31 March 2025
22,132
THRIVE THERAPEUTIC SOFTWARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 8 -
5
Fixed asset investments
2026
2025
£
£
Shares in group undertakings and participating interests
1
1
6
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
92,605
161,542
Other debtors
87,687
201,931
180,292
363,473
7
Creditors: amounts falling due within one year
2026
2025
Notes
£
£
Convertible loans
103,350
103,350
Bank loans
10,822
10,555
Trade creditors
108,895
190,392
Taxation and social security
354,229
304,189
Other creditors
434,038
364,732
1,011,334
973,218
8
Creditors: amounts falling due after more than one year
2026
2025
Notes
£
£
Bank loans and overdrafts
8,298
19,120
9
Accruals and deferred income
2026
2025
£
£
Deferred revenue
1,029,785
1,086,863
THRIVE THERAPEUTIC SOFTWARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
9
Accruals and deferred income
(Continued)
- 9 -

Revenue to be recognised within one year £1,025,685 (2025: £1,080,660).

Revenue to be recognised after more than one year £4,100 (2025: £6,203).

10
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2026
2025
£
£
1,859
9,297
2026-03-31 2025-04-01 false false false 10 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr Martin L Jervis Dr. Jose A Saez Fonseca Mr Stephen Murdoch Mr Warren B R Baker Dr Adam Huxley Dr A Huxley 07928073 2025-04-01 2026-03-31 07928073 2026-03-31 07928073 2025-03-31 07928073 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2026-03-31 07928073 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-03-31 07928073 core:ComputerEquipment 2026-03-31 07928073 core:ComputerEquipment 2025-03-31 07928073 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 07928073 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 07928073 core:Non-currentFinancialInstruments core:AfterOneYear 2026-03-31 07928073 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 07928073 core:ShareCapital 2026-03-31 07928073 core:ShareCapital 2025-03-31 07928073 core:SharePremium 2026-03-31 07928073 core:SharePremium 2025-03-31 07928073 core:RetainedEarningsAccumulatedLosses 2026-03-31 07928073 core:RetainedEarningsAccumulatedLosses 2025-03-31 07928073 core:ShareCapital 2024-03-31 07928073 core:SharePremium 2024-03-31 07928073 core:RetainedEarningsAccumulatedLosses 2024-03-31 07928073 bus:Director2 2025-04-01 2026-03-31 07928073 core:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 07928073 2024-04-01 2025-03-31 07928073 core:RetainedEarningsAccumulatedLosses 2025-04-01 2026-03-31 07928073 core:IntangibleAssetsOtherThanGoodwill 2025-04-01 2026-03-31 07928073 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-04-01 2026-03-31 07928073 core:ComputerEquipment 2025-04-01 2026-03-31 07928073 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-03-31 07928073 core:DevelopmentCostsCapitalisedDevelopmentExpenditure core:InternallyGeneratedIntangibleAssets 2025-04-01 2026-03-31 07928073 core:ComputerEquipment 2025-03-31 07928073 core:CurrentFinancialInstruments 2026-03-31 07928073 core:CurrentFinancialInstruments 2025-03-31 07928073 core:Non-currentFinancialInstruments 2026-03-31 07928073 core:Non-currentFinancialInstruments 2025-03-31 07928073 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 07928073 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 07928073 bus:FRS102 2025-04-01 2026-03-31 07928073 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 07928073 bus:Director1 2025-04-01 2026-03-31 07928073 bus:Director3 2025-04-01 2026-03-31 07928073 bus:Director4 2025-04-01 2026-03-31 07928073 bus:Director5 2025-04-01 2026-03-31 07928073 bus:CompanySecretary1 2025-04-01 2026-03-31 07928073 bus:FullAccounts 2025-04-01 2026-03-31 xbrli:pure xbrli:shares iso4217:GBP